Lars H Lindholm

发表

Failure of randomisation by “sealed” envelope

Thomas Hedner, Jan Lanke, Lennart Hansson, 1999, The Lancet.

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.

Sverker Jern, Richard B Devereux, Lars H Lindholm, 2006, JAMA.

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

Karl Swedberg, Richard B. Devereux, Ralph L. Sacco, 2011, Journal of hypertension.

Cost effectiveness analyses have been carried out in Sweden

Lars H Lindholm, Lars Werko, 1996, BMJ.

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Piotr Ponikowski, Jose Luis Zamorano, Giuseppe Mancia, 2007, European heart journal.

World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries.

Giuseppe Mancia, Tony Heagerty, Lars H Lindholm, 2007, Journal of hypertension.

[ESH/ESC 2007 Guidelines for the management of arterial hypertension].

Piotr Ponikowski, Giuseppe Mancia, Margus Viigimaa, 2007, Revista espanola de cardiologia.

Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

Thomas Hedner, Ulf de Faire, Jan Lanke, 2000, The Lancet.

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Steven Snapinn, Ulf de Faire, Richard B Devereux, 2002, The Lancet.